A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector

Prostate

Volumn 74, Issue 13, 2014, Pages 1286-1296

  Wu, Ping ^a   Sokoll, Lori J ^a,b   Kudrolli, Tarana A ^a   Chowdhury, Wasim H ^a   Ma, Rong ^a   Liu, Minzhi M ^a   Rodriguez, Ronald ^a,b   Lupold, Shawn E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

adenovirus; circulating tumor cells (CTCs); coxsackie Adenovirus receptor (CAR); CTC reporter virus (CTC RV); metridia luciferase; prostate cancer; RGD peptide

Indexed keywords

ADENOVIRUS; CIRCULATING TUMOR CELLS (CTCS); COXSACKIE-ADENOVIRUS RECEPTOR (CAR); CTC REPORTER VIRUS (CTC-RV); METRIDIA LUCIFERASE; PROSTATE CANCER; RGD PEPTIDE;

CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84905898332     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22845     Document Type: Article

References (65)

1. Maheswaran S, Haber DA,. Circulating tumor cells: A window into cancer biology and metastasis. Curr Opin Genet Dev 2010; 20 (1): 96-99.
2. Ashworth TR,. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 1869; 14: 146-149.
3. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW,. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65 (4): 713-718.
4. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14 (19): 6302-6309.
5. Okegawa T, Nutahara K, Higashihara E,. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol 2009; 181 (3): 1091-1097.
6. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA,. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012; 2 (11): 995-1003.
7. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI,. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13 (7): 2023-2029.
8. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS,. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69 (7): 2912-2918.
9. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME,. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010; 56 (9): 1492-1495.
10. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S,. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2 (25): 25ra23.
11. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M,. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010; 107 (43): 18392-18397.
12. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW,. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012; 12: 78.
13. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH,. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013; 73 (8): 813-826.
14. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M,. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013; 5 (179): 179ra147.
15. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL,. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003; 61 (2): 277-281.
16. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M,. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450 (7173): 1235-1239.
17. Maestro LM, Sastre J, Rafael SB, Veganzones SB, Vidaurreta M, Martin M, Olivier C, DE La Orden VB, Garcia-Saenz JA, Alfonso R, Arroyo M, Diaz-Rubio E,. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res 2009; 29 (11): 4839-4843.
18. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H, Siewert JR,. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002; 49 (4): 150-158.
19. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, Assmann G, Zanker KS,. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996; 56 (20): 4556-4561.
20. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW,. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998; 95 (8): 4589-4594.
21. Meye A, Bilkenroth U, Schmidt U, Fussel S, Robel K, Melchior AM, Blumke K, Pinkert D, Bartel F, Linne C, Taubert H, Wirth MP,. Isolation and enrichment of urologic tumor cells in blood samples by a semi-Automated CD45 depletion autoMACS protocol. Int J Oncol 2002; 21 (3): 521-530.
22. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD,. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002; 8 (5): 1085-1091.
23. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P,. Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156 (1): 57-63.
24. Mohamed H, Murray M, Turner JN, Caggana M,. Isolation of tumor cells using size and deformation. J Chromatogr A 2009; 1216 (47): 8289-8295.
25. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC,. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007; 1162 (2): 154-161.
26. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D,. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82 (9): 2605-2610.
27. Cruz I, Ciudad J, Cruz JJ, Ramos M, Gomez-Alonso A, Adansa JC, Rodriguez C, Orfao A,. Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol 2005; 123 (1): 66-74.
28. Cabioglu N, Igci A, Yildirim EO, Aktas E, Bilgic S, Yavuz E, Muslumanoglu M, Bozfakioglu Y, Kecer M, Ozmen V, Deniz G,. An ultrasensitive tumor enriched flow-cytometric assay for detection of isolated tumor cells in bone marrow of patients with breast cancer. Am J Surg 2002; 184 (5): 414-417.
29. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI,. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15 (6): 2091-2097.
30. Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ,. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005; 65 (3): 616-621.
31. Todenhofer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kuhs U, Gerber V, Fetisch J, Schilling D, Hauch S, Stenzl A, Schwentner C,. Preliminary experience on the use of the Adnatest(R) system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 2012; 32 (8): 3507-3513.
32. Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C,. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol 2013; 14: 6.
33. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H, Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T,. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 2009; 119 (10): 3172-3181.
34. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR,. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57 (13): 2559-2563.
35. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW,. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61 (20): 7464-7472.
36. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR,. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61 (2): 517-525.
37. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G,. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14 (1): 107-117.
38. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I,. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14 (11): 1570-1573.
39. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT,. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72 (3): 1844-1852.
40. Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE,. Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Res 2010; 70 (23): 9549-9553.
41. Carette JE, Graat HC, Schagen FH, Abou El, Hassan MA, Gerritsen WR, van Beusechem VW,. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-Acceptor site. J Gene Med 2005; 7 (8): 1053-1062.
42. Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M,. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 2005; 65 (22): 10154-10158.
43. Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R,. Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses. Mol Ther 2007; 15 (8): 1495-1503.
44. Hoti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R,. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses. Cancer Gene Ther 2010; 17 (8): 585-597.
45. Lupold SE, Johnson T, Chowdhury WH, Rodriguez R,. A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the beta-Actin promoter and enhancer. PLoS ONE 2012; 7 (5): e36535.
46. Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R,. A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Res 2007; 35 (20): e138.
47. Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, Gerritsen WR,. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000; 7 (6): 901-904.
48. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, Hunger SP, Duke RC, DeGregori J,. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci U S A 1998; 95 (22): 13159-13164.
49. Shaw AR, Ziff EB,. Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families. Cell 1980; 22 (3): 905-916.
50. Thomas GP, Mathews MB,. DNA replication and the early to late transition in adenovirus infection. Cell 1980; 22 (2 Pt 2): 523-533.
51. Fields BN, Knipe DM, Howley PM,. Fields virology, 5th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
52. Oosterhoff D, van Beusechem VW,. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004; 4 (1): 37-57.
53. Yu DC, Sakamoto GT, Henderson DR,. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59 (7): 1498-1504.
54. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW,. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61 (16): 6012-6019.
55. Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T,. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther 2004; 10 (6): 1051-1058.
56. Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jimenez JA, Gardner TA, Jeng MH, Kao C,. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 2005; 65 (5): 1941-1951.
57. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R,. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 2006; 14 (6): 768-778.
58. Lie ALM, Bakker CT, Wesseling JG, Bosma PJ,. AdEasy-based cloning system to generate tropism expanded replicating adenoviruses expressing transgenes late in the viral life cycle. Gene Ther 2005; 12 (17): 1347-1352.
59. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT,. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72 (12): 9706-9713.
60. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
61. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F,. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res 2002; 62 (13): 3812-3818.
62. Takakura M, Kyo S, Nakamura M, Maida Y, Mizumoto Y, Bono Y, Zhang X, Hashimoto Y, Urata Y, Fujiwara T, Inoue M,. Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers. Br J Cancer 2012; 107 (3): 448-454.
63. Frisch SM, Screaton RA,. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13 (5): 555-562.
64. Kim SJ, Masago A, Tamaki Y, Akazawa K, Tsukamoto F, Sato J, Ozawa T, Tsujino Y, Noguchi S,. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat 2011; 128 (3): 765-773.
65. Ito H, Inoue H, Sando N, Kimura S, Gohda K, Sato J, Murakami K, Ito S, Odaka N, Satodate H, Kudo SE,. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: A prospective study. BMC Cancer 2012; 12: 346.